5 research outputs found
Mass testing of the JUNO experiment 20-inch PMTs readout electronics
The Jiangmen Underground Neutrino Observatory (JUNO) is a multi-purpose,
large size, liquid scintillator experiment under construction in China. JUNO
will perform leading measurements detecting neutrinos from different sources
(reactor, terrestrial and astrophysical neutrinos) covering a wide energy range
(from 200 keV to several GeV). This paper focuses on the design and development
of a test protocol for the 20-inch PMT underwater readout electronics,
performed in parallel to the mass production line. In a time period of about
ten months, a total number of 6950 electronic boards were tested with an
acceptance yield of 99.1%
Implementation and performances of the IPbus protocol for the JUNO Large-PMT readout electronics
The Jiangmen Underground Neutrino Observatory (JUNO) is a large neutrino
detector currently under construction in China. Thanks to the tight
requirements on its optical and radio-purity properties, it will be able to
perform leading measurements detecting terrestrial and astrophysical neutrinos
in a wide energy range from tens of keV to hundreds of MeV. A key requirement
for the success of the experiment is an unprecedented 3% energy resolution,
guaranteed by its large active mass (20 kton) and the use of more than 20,000
20-inch photo-multiplier tubes (PMTs) acquired by high-speed, high-resolution
sampling electronics located very close to the PMTs. As the Front-End and
Read-Out electronics is expected to continuously run underwater for 30 years, a
reliable readout acquisition system capable of handling the timestamped data
stream coming from the Large-PMTs and permitting to simultaneously monitor and
operate remotely the inaccessible electronics had to be developed. In this
contribution, the firmware and hardware implementation of the IPbus based
readout protocol will be presented, together with the performances measured on
final modules during the mass production of the electronics
Validation and integration tests of the JUNO 20-inch PMTs readout electronics
The Jiangmen Underground Neutrino Observatory (JUNO) is a large neutrino
detector currently under construction in China. JUNO will be able to study the
neutrino mass ordering and to perform leading measurements detecting
terrestrial and astrophysical neutrinos in a wide energy range, spanning from
200 keV to several GeV. Given the ambitious physics goals of JUNO, the
electronic system has to meet specific tight requirements, and a thorough
characterization is required. The present paper describes the tests performed
on the readout modules to measure their performances.Comment: 20 pages, 13 figure
Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: The incremental diagnostic value of amyloid PET with [ 18 F]-florbetapir (INDIA-FBP) study
Importance Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected in vivo with positron emission tomography (PET) ligands. Although amyloid PET has clearly demonstrated analytical validity, its clinical utility is debated.
Objective To evaluate the incremental diagnostic value of amyloid PET with florbetapir F 18 in addition to the routine clinical diagnostic assessment of patients evaluated for cognitive impairment.
Design, Setting, and Participants The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study is a multicenter study involving 18 AD evaluation units from eastern Lombardy, Northern Italy, 228 consecutive adults with cognitive impairment were evaluated for AD and other causes of cognitive decline, with a prescan diagnostic confidence of AD between 15% and 85%. Participants underwent routine clinical and instrumental diagnostic assessment. A prescan diagnosis was made, diagnostic confidence was estimated, and drug treatment was provided. At the time of this workup, an amyloid PET/computed tomographic scan was performed, and the result was communicated to physicians after workup completion. Physicians were asked to review the diagnosis, diagnostic confidence, and treatment after the scan. The study was conducted from August 5, 2013, to December 31, 2014.
Main Outcomes and Measures Primary outcomes were prescan to postscan changes of diagnosis, diagnostic confidence, and treatment.
Results Of the 228 participants, 107 (46%) were male; mean (SD) age was 70.5 (7) years. Diagnostic change occurred in 46 patients (79%) having both a previous diagnosis of AD and an amyloid-negative scan (P\u2009<\u2009.001) and in 16 (53%) of those with non-AD diagnoses and an amyloid-positive scan (P\u2009<\u2009.001). Diagnostic confidence in AD diagnosis increased by 15.2% in amyloid-positive (P\u2009<\u2009.001; effect size Cohen d\u2009=\u20091.04) and decreased by 29.9% in amyloid-negative (P\u2009<\u2009.001; d\u2009=\u2009 121.19) scans. Acetylcholinesterase inhibitors and memantine hydrochloride were introduced in 61 (65.6%) patients with positive scan results who had not previously received those drugs, and the use of the drugs was discontinued in 6 (33.3%) patients with negative scan results who were receiving those drugs (P\u2009<\u2009.001).
Conclusions and Relevance Amyloid PET in addition to routine assessment in patients with cognitive impairment has a significant effect on diagnosis, diagnostic confidence, and drug treatment. The effect on health outcomes, such as morbidity and mortality, remains to be assessed